Livzon Pharmaceutical Group Inc. (HKG:1513)

HKG:1513 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Jan 1, 2021
Cash & Equivalents	10,831	10,827	11,326	10,411	9,146	9,954
Trading Asset Securities	68.32	89.36	81.79	108.09	182.77	25.98
Cash & Short-Term Investments	10,899	10,917	11,408	10,519	9,329	9,980
Cash Growth	-2.96%	-4.30%	8.44%	12.76%	-6.52%	12.48%
Accounts Receivable	3,318	3,249	3,575	4,039	3,294	2,892
Other Receivables	42.57	59.28	51.91	31.32	64.37	92.85
Receivables	3,361	3,308	3,627	4,071	3,358	2,985
Inventory	1,900	1,998	2,061	2,045	1,663	1,488
Other Current Assets	305.48	197.44	171.11	352	322.42	174.88
Total Current Assets	16,466	16,420	17,266	16,987	14,673	14,627
Property, Plant & Equipment	4,517	4,537	4,566	4,592	4,239	3,707
Long-Term Investments	1,627	1,618	1,670	1,738	1,695	988.09
Goodwill	124.91	124.91	124.91	103.04	103.04	103.04
Other Intangible Assets	394.06	403.68	426.28	557.44	260.28	236.43
Long-Term Deferred Tax Assets	352.43	356.35	301.92	283.89	252.69	238.23
Long-Term Deferred Charges	418.7	396.25	468.62	416.74	704.41	373.49
Other Long-Term Assets	586.2	599.54	221.17	189.66	444.62	317.09
Total Assets	24,485	24,456	25,045	24,868	22,372	20,591
Accounts Payable	1,539	1,584	1,658	1,862	1,817	1,625
Accrued Expenses	143.15	3,109	3,295	3,249	2,656	2,467
Short-Term Debt	2,325	2,455	1,860	1,622	2,043	1,551
Current Portion of Long-Term Debt	84.73	36.21	647.47	-	-	-
Current Portion of Leases	-	12.53	12.2	10.44	9.28	8.54
Current Income Taxes Payable	186.15	112.88	181.58	92.57	97.45	179.51
Current Unearned Revenue	70.6	124.63	138	226.19	167.8	104.45
Other Current Liabilities	2,887	191.27	294.49	334.42	134.34	147.17
Total Current Liabilities	7,235	7,625	8,087	7,397	6,925	6,083
Long-Term Debt	1,433	1,466	1,613	1,974	636.78	360.32
Long-Term Leases	14.72	13.1	9.03	11.61	5.27	10.1
Long-Term Unearned Revenue	218.54	238.42	269.37	273.21	258.88	276.14
Long-Term Deferred Tax Liabilities	208.73	207.39	209.81	191.96	156.89	143.28
Other Long-Term Liabilities	-	-	90	84	78	78
Total Liabilities	9,110	9,550	10,278	9,932	8,061	6,951
Common Stock	911.35	911.35	923.94	935.55	937.87	944.84
Additional Paid-In Capital	-	529.24	1,322	1,422	1,629	1,457
Retained Earnings	13,143	12,506	11,653	11,182	10,461	9,682
Treasury Stock	-517.95	-196.62	-	-55.94	-71.21	-250.06
Comprehensive Income & Other	629.36	112.18	143.07	391.64	46.55	273.78
Total Common Equity	14,166	13,862	14,042	13,876	13,004	12,107
Minority Interest	1,210	1,043	724.21	1,060	1,307	1,533
Shareholders' Equity	15,375	14,906	14,767	14,936	14,311	13,640
Total Liabilities & Equity	24,485	24,456	25,045	24,868	22,372	20,591
Total Debt	3,857	3,983	4,141	3,619	2,694	1,930
Net Cash (Debt)	7,042	6,934	7,266	6,901	6,635	8,050
Net Cash Growth	-8.15%	-4.57%	5.29%	4.01%	-17.58%	7.16%
Net Cash Per Share	7.73	7.53	7.81	7.37	7.09	8.58
Filing Date Shares Outstanding	894.67	908.91	923.94	932.23	929.97	932.47
Total Common Shares Outstanding	894.67	908.91	923.94	932.23	929.97	944.84
Working Capital	9,230	8,795	9,179	9,591	7,748	8,544
Book Value Per Share	15.83	15.25	15.20	14.88	13.98	12.81
Tangible Book Value	13,647	13,334	13,491	13,216	12,640	11,768
Tangible Book Value Per Share	15.25	14.67	14.60	14.18	13.59	12.45
Buildings	-	3,912	3,745	-	3,123	2,970
Machinery	-	4,817	4,551	7,577	3,764	3,216
Construction In Progress	-	257.37	289.31	602.44	554.58	385.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.